ZA202001586B - Variant rnai - Google Patents
Variant rnaiInfo
- Publication number
- ZA202001586B ZA202001586B ZA2020/01586A ZA202001586A ZA202001586B ZA 202001586 B ZA202001586 B ZA 202001586B ZA 2020/01586 A ZA2020/01586 A ZA 2020/01586A ZA 202001586 A ZA202001586 A ZA 202001586A ZA 202001586 B ZA202001586 B ZA 202001586B
- Authority
- ZA
- South Africa
- Prior art keywords
- rnai
- recombinant
- disease
- further provided
- vectors
- Prior art date
Links
- 108091030071 RNAI Proteins 0.000 title abstract 4
- 230000009368 gene silencing by RNA Effects 0.000 abstract 3
- 208000023105 Huntington disease Diseases 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561843P | 2017-09-22 | 2017-09-22 | |
| PCT/US2018/052221 WO2019060726A1 (en) | 2017-09-22 | 2018-09-21 | Variant rnai |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202001586B true ZA202001586B (en) | 2024-01-31 |
Family
ID=64017428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/01586A ZA202001586B (en) | 2017-09-22 | 2020-03-13 | Variant rnai |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11603529B2 (enExample) |
| EP (1) | EP3684932A1 (enExample) |
| JP (1) | JP7248658B2 (enExample) |
| KR (1) | KR102686857B1 (enExample) |
| CN (1) | CN111356763B (enExample) |
| AR (1) | AR113134A1 (enExample) |
| AU (2) | AU2018335410B2 (enExample) |
| BR (1) | BR112020005569A2 (enExample) |
| CA (1) | CA3076191A1 (enExample) |
| CO (1) | CO2020003187A2 (enExample) |
| IL (1) | IL273394B2 (enExample) |
| MX (2) | MX2020003095A (enExample) |
| MY (1) | MY205041A (enExample) |
| PH (1) | PH12020550117A1 (enExample) |
| SG (1) | SG11202002488UA (enExample) |
| TW (1) | TWI902656B (enExample) |
| UY (1) | UY37897A (enExample) |
| WO (1) | WO2019060726A1 (enExample) |
| ZA (1) | ZA202001586B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3255657A1 (en) | 2015-02-10 | 2025-12-01 | Genzyme Corporation | VARIANT RNAi |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| MX2020003095A (es) | 2017-09-22 | 2020-10-15 | Genzyme Corp | Arni variante. |
| CN112980837B (zh) * | 2019-12-13 | 2023-07-04 | 深圳艾码生物科技有限公司 | 一种抑制HTT基因表达的siRNA及其前体和应用 |
| EP4133090A1 (en) * | 2020-04-07 | 2023-02-15 | Lung Biotechnology PBC | Adenoviral expression vector and methods and cell lines for production |
| EP4317434A4 (en) * | 2021-03-30 | 2025-04-16 | Nanjing University | RNA DELIVERY SYSTEM FOR THE TREATMENT OF HUNTINGTON'S DISEASE |
| JP2025538441A (ja) * | 2022-11-16 | 2025-11-28 | フォージ バイオロジクス，インコーポレイテッド | アデノウイルスヘルパープラスミド |
| WO2025160434A1 (en) * | 2024-01-26 | 2025-07-31 | Genzyme Corporation | Artificial micrornas targeting huntington's disease |
| WO2025250616A1 (en) * | 2024-05-29 | 2025-12-04 | The Regents Of The University Of California | Methods and materials for treating huntington's disease |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2264482A1 (en) | 1996-09-06 | 1998-03-12 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
| JP2004101787A (ja) | 2002-09-09 | 2004-04-02 | Fuji Xerox Co Ltd | 画像形成装置及び現像装置 |
| WO2004029212A2 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| AU2004239114B2 (en) | 2003-05-14 | 2008-03-13 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
| CA2596588C (en) * | 2005-01-31 | 2017-06-27 | University Of Iowa Research Foundation | Nucleic acid silencing of huntington's disease gene |
| US8283151B2 (en) | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
| US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US8173614B2 (en) * | 2007-01-03 | 2012-05-08 | Medtronic, Inc. | Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof |
| WO2008134646A2 (en) | 2007-04-26 | 2008-11-06 | University Of Iowa Research Foundation | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| DK2164967T3 (en) | 2007-05-31 | 2015-10-19 | Univ Iowa Res Found | Reduction of off-target rna interferenstoksicitet |
| CA2711585A1 (en) | 2008-02-04 | 2009-08-13 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
| US8318924B2 (en) | 2008-02-14 | 2012-11-27 | Michael Paul Marie Gantier | Immunostimulatory siRNA molecules |
| FR2929292A1 (fr) * | 2008-03-28 | 2009-10-02 | Exonhit Therapeutics S A Sa | Procede et methodes de diagnostic de la maladie d'alzheimer |
| US8796238B2 (en) | 2009-09-17 | 2014-08-05 | Sigma-Aldrich Co. Llc | Short RNA mimetics |
| DK2561073T3 (en) * | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CN103502458B (zh) | 2011-02-17 | 2016-11-16 | 宾夕法尼亚大学托管会 | 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法 |
| CA2865011C (en) * | 2012-02-29 | 2021-06-15 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
| CN103224556B (zh) * | 2013-01-31 | 2015-04-15 | 清华大学 | 亨廷顿舞蹈症的靶位蛋白质及其编码基因和应用 |
| US9550989B2 (en) | 2013-10-03 | 2017-01-24 | Washington University | Rational design of microRNA-siRNA chimeras for multi-functional target suppression |
| MX391904B (es) | 2013-11-11 | 2025-03-12 | Sangamo Biosciences Inc | Un represor genetico para usarse en el tratamiento de la enfermedad de huntington. |
| PT3628334T (pt) * | 2014-03-21 | 2023-09-26 | Genzyme Corp | Terapia genética para retinopatia pigmentar |
| LT3137497T (lt) | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| AU2015264263B2 (en) | 2014-05-20 | 2021-08-05 | University Of Iowa Research Foundation | Huntington's disease therapeutic compounds |
| AU2015370903B2 (en) * | 2014-12-24 | 2021-06-17 | Uniqure Ip B.V. | RNAi induced huntingtin gene suppression |
| CA3255657A1 (en) | 2015-02-10 | 2025-12-01 | Genzyme Corporation | VARIANT RNAi |
| IL297576B2 (en) * | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| MX2020003095A (es) | 2017-09-22 | 2020-10-15 | Genzyme Corp | Arni variante. |
| TW202509215A (zh) | 2018-08-03 | 2025-03-01 | 美商健臻公司 | 針對α-突觸核蛋白的變體RNAi |
-
2018
- 2018-09-21 MX MX2020003095A patent/MX2020003095A/es unknown
- 2018-09-21 WO PCT/US2018/052221 patent/WO2019060726A1/en not_active Ceased
- 2018-09-21 IL IL273394A patent/IL273394B2/en unknown
- 2018-09-21 MY MYPI2020001372A patent/MY205041A/en unknown
- 2018-09-21 UY UY0001037897A patent/UY37897A/es not_active Application Discontinuation
- 2018-09-21 CN CN201880073881.6A patent/CN111356763B/zh active Active
- 2018-09-21 AR ARP180102723A patent/AR113134A1/es unknown
- 2018-09-21 KR KR1020207011227A patent/KR102686857B1/ko active Active
- 2018-09-21 JP JP2020516666A patent/JP7248658B2/ja active Active
- 2018-09-21 EP EP18793503.6A patent/EP3684932A1/en active Pending
- 2018-09-21 BR BR112020005569-7A patent/BR112020005569A2/pt unknown
- 2018-09-21 SG SG11202002488UA patent/SG11202002488UA/en unknown
- 2018-09-21 US US16/649,042 patent/US11603529B2/en active Active
- 2018-09-21 CA CA3076191A patent/CA3076191A1/en active Pending
- 2018-09-21 AU AU2018335410A patent/AU2018335410B2/en active Active
- 2018-09-25 TW TW107133661A patent/TWI902656B/zh active
-
2020
- 2020-03-13 ZA ZA2020/01586A patent/ZA202001586B/en unknown
- 2020-03-16 PH PH12020550117A patent/PH12020550117A1/en unknown
- 2020-03-18 CO CONC2020/0003187A patent/CO2020003187A2/es unknown
- 2020-03-19 MX MX2025008949A patent/MX2025008949A/es unknown
-
2023
- 2023-02-15 US US18/169,779 patent/US12331296B2/en active Active
-
2025
- 2025-06-03 US US19/227,261 patent/US20250290075A1/en active Pending
- 2025-07-03 AU AU2025205089A patent/AU2025205089A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025008949A (es) | Arni variante | |
| MX2022013005A (es) | Arni variante. | |
| WO2018204803A8 (en) | Compositions and methods of treating huntington's disease | |
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| MX2023013435A (es) | Composiciones y metodos para expresar otoferlina. | |
| SA520420518B1 (ar) | تبديل الانتحاء النسيجي للفَيروسات المُرتَبِط بالفَيروس الغُدِّيّ | |
| SG10201901482XA (en) | Oncolytic adenovirus encoding a b7 protein | |
| BR112017005892A2 (pt) | variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma | |
| MX2018014152A (es) | Composiciones y métodos para tratar la enfermedad de huntington. | |
| PH12021550254A1 (en) | Variant rnai against alpha-synuclein | |
| BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
| MX2017015666A (es) | Agentes de anticuerpos similares al receptor de celulas t, especificos para peptidos de proteina latente de membrana 2a del virus de epstein-barr (ebv) presentado por antigeno leucocitario humano (hla). | |
| BR112017005235A2 (pt) | vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc) | |
| WO2018189661A3 (en) | Methods and compounds for treating diabetes | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| DOP2017000185A (es) | Arni variante | |
| EA201992032A1 (ru) | Композиции, пригодные при лечении спинальной мышечной атрофии | |
| TH1701004531A (th) | แวเรียนท์RNAi | |
| EA201890595A1 (ru) | Онколитический аденовирус, кодирующий белок b7 | |
| BR112017017867A2 (pt) | métodos e composições para tratamento de doenças oculares genéticas | |
| BR112016021017A2 (pt) | Partículas de raav, composição e uso das mesmas na terapia gênica para retinite pigmentosa |